1887

Abstract

The aim of this study was to establish the importance of detecting fluoroquinolone (FQ) resistance in multidrug resistant (MDR) , and to show the usefulness of a hybridization-based line probe assay (LiPA) for detecting mutations. Thirty-three MDR isolates were collected from a total of sixty MDR isolates identified in Japan over 6 months during a national surveillance study in 2002. Seventeen MDR isolates were collected by the National Center for Global Health and Medicine in Japan over 6 years from 2003 to 2008. These 50 isolates were examined for FQ susceptibility, and analysed by LiPA and sequencing. Among them, 22 (44 %) showed FQ resistance. All FQ-resistant isolates had at least one mutation in . The results of the LiPA were fully consistent with the DNA sequencing results. Given that on the basis of our results almost half of the MDR isolates in Japan might have resistance to FQ, it is important to monitor FQ resistance in patients with MDR tuberculosis (TB), as well as with drug-susceptible TB, prior to commencing treatment. For the detection of FQ resistance, LiPA is useful and can rapidly and efficiently assess FQ resistance.

Loading

Article metrics loading...

/content/journal/jmm/10.1099/jmm.0.024729-0
2011-02-01
2021-07-27
Loading full text...

Full text loading...

/deliver/fulltext/jmm/60/2/184.html?itemId=/content/journal/jmm/10.1099/jmm.0.024729-0&mimeType=html&fmt=ahah

References

  1. Ando H., Mitarai S., Kondo Y., Suetake T., Sekiguchi J. I., Kato S., Mori T., Kirikae T. 2010; Pyrazinamide resistance in multidrug-resistant Mycobacterium tuberculosis isolates in Japan. Clin Microbiol Infect 16:1164–1168 [CrossRef]
    [Google Scholar]
  2. Aubry A., Veziris N., Cambau E., Truffot-Pernot C., Jarlier V., Fisher L. M. 2006; Novel gyrase mutations in quinolone-resistant and -hypersusceptible clinical isolates of Mycobacterium tuberculosis : functional analysis of mutant enzymes. Antimicrob Agents Chemother 50:104–112 [CrossRef]
    [Google Scholar]
  3. Aziz M., Laszlo A., Raviglione M. C., Rieder H. L., Espinal M. A., Wright A. 2003 Guidelines for Surveillance of Drug Resistance in Tuberculosis Geneva: World Health Organization;
    [Google Scholar]
  4. Caminero J. A. 2010; Multidrug-resistant tuberculosis: epidemiology, risk factors and case finding. Int J Tuberc Lung Dis 14:382–390
    [Google Scholar]
  5. Conde M. B., Efron A., Loredo C., De Souza G. R., Graca N. P., Cezar M. C., Ram M., Chaudhary M. A., Bishai W. R. other authors 2009; Moxifloxacin versus ethambutol in the initial treatment of tuberculosis: a double-blind, randomised, controlled phase II trial. Lancet 373:1183–1189 [CrossRef]
    [Google Scholar]
  6. Fujiki A. 2001 TB Bacteriology Examination to Stop TB Tokyo: The Research Institute of Tuberculosis;
    [Google Scholar]
  7. Guillemin I., Jarlier V., Cambau E. 1998; Correlation between quinolone susceptibility patterns and sequences in the A and B subunits of DNA gyrase in mycobacteria. Antimicrob Agents Chemother 42:2084–2088
    [Google Scholar]
  8. Johnston J. C., Shahidi N. C., Sadatsafavi M., Fitzgerald J. M. 2009; Treatment outcomes of multidrug-resistant tuberculosis: a systematic review and meta-analysis. PLoS ONE 4:e6914 [CrossRef]
    [Google Scholar]
  9. Sekiguchi J., Miyoshi-Akiyama T., Augustynowicz-Kopec E., Zwolska Z., Kirikae F., Toyota E., Kobayashi I., Morita K., Kudo K. other authors 2007a; Detection of multidrug resistance in Mycobacterium tuberculosis . J Clin Microbiol 45:179–192 [CrossRef]
    [Google Scholar]
  10. Sekiguchi J., Nakamura T., Miyoshi-Akiyama T., Kirikae F., Kobayashi I., Augustynowicz-Kopec E., Zwolska Z., Morita K., Suetake T. other authors 2007b; Development and evaluation of a line probe assay for rapid identification of pncA mutations in pyrazinamide-resistant Mycobacterium tuberculosis strains. J Clin Microbiol 45:2802–2807 [CrossRef]
    [Google Scholar]
  11. Sotgiu G., Ferrara G., Matteelli A., Richardson M. D., Centis R., Ruesch-Gerdes S., Toungoussova O., Zellweger J. P., Spanevello A. other authors 2009; Epidemiology and clinical management of XDR-TB: a systematic review by TBNET. Eur Respir J 33:871–881 [CrossRef]
    [Google Scholar]
  12. TRC 2007; Drug-resistant Mycobacterium tuberculosis in Japan: a nationwide survey, 2002. Int J Tuberc Lung Dis 11:1129–1135
    [Google Scholar]
  13. Van Deun A., Martin A., Palomino J. C. 2010a; Diagnosis of drug-resistant tuberculosis: reliability and rapidity of detection. Int J Tuberc Lung Dis 14:131–140
    [Google Scholar]
  14. Van Deun A., Maug A. K., Salim M. A., Das P. K., Sarker M. R., Daru P., Rieder H. L. 2010b; Short, highly effective, and inexpensive standardized treatment of multidrug-resistant tuberculosis. Am J Respir Crit Care Med 182:684–692 [CrossRef]
    [Google Scholar]
  15. Wang J. Y., Hsueh P. R., Jan I. S., Lee L. N., Liaw Y. S., Yang P. C., Luh K. T. 2006; Empirical treatment with a fluoroquinolone delays the treatment for tuberculosis and is associated with a poor prognosis in endemic areas. Thorax 61:903–908 [CrossRef]
    [Google Scholar]
  16. Yew W. W., Lange C., Leung C. C. 2010; Treatment of tuberculosis update; 2010 Eur Respir J (in press). doi: 10.1183/09031936.00033010
  17. Yoon Y. S., Lee H. J., Yoon H. I., Yoo C. G., Kim Y. W., Han S. K., Shim Y. S., Yim J. J. 2005; Impact of fluoroquinolones on the diagnosis of pulmonary tuberculosis initially treated as bacterial pneumonia. Int J Tuberc Lung Dis 9:1215–1219
    [Google Scholar]
  18. Zhang Y., Telenti A. 2000 Genetics of Drug Resistance in Mycobacterium tuberculosis Washington, DC: American Society for Microbiology;
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jmm/10.1099/jmm.0.024729-0
Loading
/content/journal/jmm/10.1099/jmm.0.024729-0
Loading

Data & Media loading...

Most cited this month Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error